Karen M. Anderson Sells 6,471 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 6,471 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $16.86, for a total transaction of $109,101.06. Following the completion of the sale, the insider now owns 54,322 shares of the company’s stock, valued at $915,868.92. This trade represents a 10.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock opened at $17.24 on Thursday. Centessa Pharmaceuticals plc has a twelve month low of $7.38 and a twelve month high of $18.97. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $16.74 and a two-hundred day simple moving average of $15.28. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of -11.27 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. On average, analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its stake in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after acquiring an additional 1,509 shares during the period. Walleye Capital LLC bought a new position in shares of Centessa Pharmaceuticals in the 3rd quarter worth $187,000. China Universal Asset Management Co. Ltd. raised its position in shares of Centessa Pharmaceuticals by 99.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock worth $217,000 after acquiring an additional 6,785 shares in the last quarter. Finally, Harbour Capital Advisors LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter worth $259,000. 82.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CNTA shares. Guggenheim raised their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. TD Cowen began coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.